Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment

Eitemau Tebyg

• Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up
  gan: Fleischmann, Roy, et al.
  Cyhoeddwyd: (2020)
• Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
  gan: Keystone, Edward C, et al.
  Cyhoeddwyd: (2017)
• Association of High Serum Interleukin‐6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis
  gan: Boyapati, Anita, et al.
  Cyhoeddwyd: (2020)
• Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes
  gan: Genovese, Mark C, et al.
  Cyhoeddwyd: (2018)
• Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
  gan: Strand, Vibeke, et al.
  Cyhoeddwyd: (2016)